Identification of B- and T-cell epitopes of BB, a carrier protein derived from the G protein of Streptococcus strain G148

Clinical and Diagnostic Laboratory Immunology

Volumn 10, Issue 1, 2003, Pages 125-132

  Goetsch, Liliane ^a   Haeuw, Jean Francois ^a   Champion, Thierry ^a   Lacheny, Christine ^a   N'Guyen, Thien ^a   Beck, Alain ^a   Corvaia, Nathalie ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BACTERIAL PROTEIN; BB CARRIER PROTEIN; CARRIER PROTEIN; EPITOPE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G ANTIBODY; POLYSACCHARIDE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; STREPTOCOCCAL PROTEIN G; SYNTHETIC PEPTIDE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BINDING SITE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; STRAIN DIFFERENCE; STREPTOCOCCUS; T LYMPHOCYTE; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; BACTERIAL PROTEINS; CARRIER PROTEINS; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDES; POLYSACCHARIDES; VIRAL PROTEINS;

EID: 0037247022     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.10.1.125-132.2003     Document Type: Article

References (45)

1. Alexander, J., M. F. del Guercio, A. Maewal, L. Qiao, J. Fikes, R. W. Chesnut, J. Paulson, D. R. Bundle, S. DeFrees, and A. Sette. 2000. Linear PADRE T helper epitope and carbohydrate B-cell epitope conjugates induce specific high titer IgG antibody responses, J. Immunol. 164:1625-1633.
2. Bjorck, L., W. Kastern, G. Lindahl, and K. Wideback. 1987. Streptococcal protein G, expressed by streptococci or by Escherichia coli, has separate binding sites for human albumin and IgG. Mol. Immunol. 24:1113-1122.
3. Bockenstedt, L. K., E. Fikrig, S. W. Barthold, R. A. Flavell, and F. S. Kantor. 1996. Identification of a Borrelia burgdorferi OspA T-cell epitope that promotes anti-OspA IgG in mice. J. Immunol. 157:5496-5502.
4. Chu, C., R. Schneerson, J. B. Robbins, and S. C. Rastogi. 1983. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect. Immun. 40:245-256.
5. Dalum, I., M. R. Jensen, P. Hindersson, H. I. Eisner, and S. Mouritsen. 1996. Breaking of B cell tolerance toward a highly conserved self protein. J. Immunol. 157:4796-4804.
6. Dalum, I., M. R. Jensen, K. Gregorius, C. M. Thomasen, H. I. Elsner, and S. Mouritsen. 1997. Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope. Mol. Immunol. 34:1113-1120.
7. Davey, S. 1996. The vaccine challenge, p. 1-25. In State of the world's vaccines and immunization. World Health Organization/United Nations Children's Fund, Geneva, Switzerland.
8. + cells on tetanus and diphtheria toxins. J. Infect. Dis. 181:1001-1009.
9. Etlinger, H. M., D. Gillessen, H. W. Lahm, H. Matile, H. J. Schonfeld, and A. Trzeciak. 1990. Use of prior vaccinations for the development of new vaccines. Science 249:423-425.
10. Falkenberg, C., L. Bjorck, and B. Akerstrom. 1992. Localization of the binding site for streptococcal protein G on human serum albumin: identification of a 5.5-kilodalton protein G binding albumin fragment. Biochemistry 31:1451-1457.
11. Galelli, A., and B. Charlot. 1990. Clonal anergy of memory B cells in epitope-specific regulation. J. Immunol. 145:2397-2405.
12. Geysen, H. M., S. J. Rodda, T. J. Mason, G. Tribick, and P. G. Schoofs. 1987. Strategies for epitope analysis using peptide synthesis. J. Immunol. Methods 102:259-274.
13. Goetsch, L., A. Gonzalez, H. Plotnicky-Gilquin, J. F. Haeuw, J. P. Aubry, A. Beck, J. Y. Bonnefoy, and N. Corvaia. 2001. Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae. Infect. Immun. 69:6434-6444.
14. 197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs. Vaccine 15:1341-1343.
15. Haeuw, J. F., I. Rauly, L. Zanna, C. Libon, C. Andreoni, T. Nguyen, T. Baussant, J. Y. Bonnefoy, and A. Beck. 1998. The recombinant Klebsiella pneumoniae outer membrane protein OmpA has carrier properties for conjugated antigenic peptides. Eur. J. Chem. 255:446-454.
16. Herzenberg, L. A., and T. Tokuhisa. 1982. Epitope-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses. J. Exp. Med. 155:1730-1740.
17. Ho, P. C., D. A. Mutch, K. D. Winkel, A. J. Saul, G. L. Jones, T. J. Doran, and C. M. Rzepczyk. 1990. Identification of two promiscuous T-cell epitopes from tetanus toxin. Eur. J. Immunol. 20:477-483.
18. Hoffmann, P., M. Loleit, K. Mittenbuhler, W. Beck, K. H. Wiesmuller, G. Jung, and W. G. Bessler. 1997. Induction of an epitope-specific humoral immune response by lipopeptide-hapten conjugates: enhancement of the anti-melittin response by a synthetic T helper (Th)-cell epitope. FEMS Immunol. Med. Microbiol. 17:225-234.
19. Käyhty, H., H. Ahman, P. R. Rönnberg, R. Tillikainen, and J. Eskola. 1995. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J. Infect. Dis. 172:1273-1278.
20. Kraulis, P. J., P. Jonasson, P. A. Nygren, M. Uhlen, L. Jendeberg, B. Nilsson, and J. Kordel. 1996. The serum albumin-binding domain of streptococcal protein G is a three-helical bundle: a heteronuclear NMR study. FEBS Letter 378:190-194.
21. Kurikka, S., H. Käyhty, H. Peltola, L. Saarinen, J. Eskola, and H. Mäkelä. 1995. Neonatal immunization: response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatrics 95:815-822.
22. Libon, C., N. Corvaïa, J. F. Haeuw, T. N. Nguyen, S. Stahl, J. J. Bonnefoy, and C. Andreoni. 1999. The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G130-230 RSV-A protein. Vaccine 17:406-414.
23. Linhult, M., H. K. Binz, M. Uhlen, and S. Hober. 2002. Mutational analysis of the interaction between albumin-binding domain from streptococcal protein G and human serum albumin. Protein Sci. 11:206-213.
24. Lo-Man, R., S. Vichier-Guerre, S. Bay, E. Deriaud, D. Cantacuzene, and C. Leclerc. 2001. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope. J. Immunol. 166:2849-2854.
25. Makrides, S. C., P. A. Nygren, B. Andrews, P. J. Ford, K. S. Evans, E. G. Hayman, H. Adari, M. Uhlen, and C. A. Toth. 1996. Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. J. Pharmacol. Exp. Ther. 277:534-5442.
26. Meaji, N. J., A. M. Bray, and H. M. Geysen. 1990. Multi-pin peptide synthesis strategy for T-cell determinant analysis. J. Immunol. Methods 134:23-33.
27. Nygren, P. A., M. Eliasson, E. Palmcrantz, L. Abrahmsen, and M. Uhlen. 1988. Analysis and use of the serum albumin binding domains of streptococcal protein G. J. Mol. Recogn. 1:60-74.
28. Nygren, P. A., C. Ljungquist, H. Tromborg, K. Nustad, and M. Uhlen. 1990. Species-dependent binding of serum albumins to the streptococcal receptor protein G. Eur. J. Biochem. 193:143-148.
29. Nygren, P. A., P. Flodby, R. Andersson, H. Wigzell, and M. Uhlén. 1991. In vivo stabilization of a human recombinant CD4 derivative by fusion to a serum-albumin-binding receptor. Vaccines 91:363-368.
30. Panina-Bordignon, P., A. Tan, A. Termijtelen, S. Demotz, G. Corradin, and A. Lanzavecchia. 1989. Universally immunogenic T-cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:2237-2242.
31. Peeters, C. C., A. M. Tenbergen-Meekes, J. T. Poolman, M. Beurret, B. J. Zegers, and G. T. Rijkers. 1991. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect. Immun. 59:3504-3510.
32. Plotnicky-Gilquin, H., L. Goetsch, T. Huss, T. Champion, A. Beck, J. F. Haeuw, T. N. Nguyen, J. Y. Bonnefoy, N. Corvaia, and U. F. Power. 1999. Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein. J. Virol. 73:5637-5645.
33. Power, U. F., T. N. Nguyen, E. Rietveld, R. L. de Swart, J. Groen, A. D. Osterhaus, R. de Groot, N. Corvaia, A. Beck, N. Bouveret-Le-Cam, and J. Y. Bonnefoy. 2001. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J. Infect. Dis. 184:1456-1460.
34. + cells on diphtheria toxin: structural features of sequence segments forming epitopes recognized by most subjects. Eur. J. Immunol. 25:3207-3214.
35. Rauly, I., L. Goetsch, J. F. Haeuw, C. Tardieux, T. Baussant, J. Y. Bonnefoy, and N. Corvaia. 1999. Carrier properties of a protein derived from outer membrane protein A of Klebsiella pneumoniae. Infect. Immun. 67:5547-5551.
36. Reece, J. C., H. M. Geysen, and S. J. Rodda. 1993. Mapping the major human T helper epitopes of tetanus toxin. J. Immunol. 151:6175-6184.
37. Reece, J. C., D. L. McGregor, H. M. Geysen, and S. J. Rodda. 1994. Scanning for T helper epitopes with human PBMC using pools of short synthetic peptides. J. Immunol. Methods 172:241-254.
38. Reuter, G., and R. Schauer. 1994. Determination of sialic acids. Methods Enzymol. 230:168-199.
39. Schutze, M. P., C. Leclerc, M. Jolivet, F. Audibert, and L. Chedid. 1985. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J. Immunol. 135:2319-2322.
40. Schutze, M. P., E. Deriaud, G. Przewlocki, and C. Leclerc. 1989. Carrier-induced epitopic suppression is initiated through clonal dominance. J, Immunol. 142:2635-2640.
41. Sjolander, A., P. A. Nygren, S. Stahl, K. Berzins, M. Uhlen, P. Perlmann, and R. Andersson. 1997. The serum albumin-binding region of streptococcal protein G: a bacterial fusion partner with carrier-related properties. J. Immunol. Methods 201:115-123.
42. Stahl, S., A. Sjolander, P. A. Nygren, K. Berzins, P. Perlmann, and M. Uhlen, M. 1989. A dual expression system for the generation, analysis and purification of antibodies to a repeated sequence of the Plasmodium falciparum antigen Pf155/RESA. J. Immunol. Methods 124:43-52.
43. Valmori, D., A. Pessi, E. Bianchi, and G. Corradin. 1992. Use of human universally antigenic tetanus toxin T-cell epitopes as carriers for human vaccination. J. Immunol. 149:717-721.
44. Watanabe, M., K. A. Reimann, P. A. DeLong, T. Liu, R. A. Fisher, and N. L. Letvin. 1984. Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques. Nature 337:267-270.
45. Zauner, W., K. Lingnau, F. Mattner, A. von Gabain, and M. Buschle. 2001. Defined synthetic vaccines. Biol. Chem. 382:581-595.